Authors


Lars Widdel, MD

Latest:

Metastatic Papillary Adenocarcinoma in a 22-Year-Old: Is Her History of Mayer-Rokitansky-Küster-Hauser Syndrome Causative or Incidental?

A 22-year-old college student with primary amenorrhea due to Müllerian agenesis presented with a headache, dysarthria, nausea, vomiting, and left upper extremity weakness. MRI of the brain showed numerous intracranial lesions.


Lary Robinson, MD

Latest:

Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancer

Lung cancer is the most common cancer diagnosed in men and women in the United States, and is the leading cause of cancer death.Over 160,000 individuals died as a result of lung cancer in 2008.[1] This number amounted to more than the number of deaths from colon, breast, and prostate cancers combined. The majority of lung cancer cases are non–small-cell lung cancer (NSCLC), and the poor outcomes are attributed to the high rate of metastases associated with this disease.


Lasika Seneviratne, MD

Latest:

Incidence and Management of AIDS-Related Lymphoma

Over time, the spectrum of the acquired immune deficiency syndrome (AIDS) epidemic has changed, especially with the advent of highly active antiretroviral therapy (HAART). The goal of this article is to delineate changes


László Tabár, MD

Latest:

Breast Cancer Screening: The Evolving Evidence

In this paper, the historic and recent evidence supporting the value of breast cancer screening will be described, along with the underpinnings of the current debate over the relative and absolute benefit of regular mammography screening.


Laura A. Colangelo, MS

Latest:

Speech and Swallowing Rehabilitation for Head and Neck Cancer Patients

Head and neck cancer and its treatment frequently cause changes in both speech and swallowing, which affect the patient's quality of life and ability to function in society. The exact nature and severity of the post-treatment changes depend on the location of the tumor, the choice of treatment, and the availability and use of speech and swallowing therapy during the first 3 months after treatment. This paper reviews the literature on speech and swallowing problems in various types of treated head and neck cancer patients. Effective swallowing rehabilitation depends on the inclusion of a video-fluorographic assessment of the patient's oropharyngeal swallow in the post-treatment evaluation. Pilot data support the use of range of motion (ROM) exercises for the jaw, tongue, lips, and larynx in the first 3 months after oral or oropharyngeal ablative surgical procedures, as patients who perform ROM exercises on a regular basis exhibit significantly greater improvement in global measures of both speech and swallowing, as compared with patients who do not do these exercises. [ONCOLOGY 11(5):651-659, 1997]


Laura A. Siminoff, PhD

Latest:

Surviving the Stresses of Clinical Oncology by Improving Communication

Armstrong and Holland’s articleprovides a clear and concisediscussion of many ofthe problems oncologists face in thehigh-pressure/high-stakes world of21st century medicine. Physicians ingeneral, and oncologists in particular,are overburdened with demandson their time, energy, and emotions.The authors present suggestions forrelieving these stresses in the formof a “survival kit.” The survival kit isinteresting because it provides an educationon how to communicate withpatients and deal with the emotionalaspects of practicing medicine.


Laura Austin, MD

Latest:

Cancer Stem Cells: Implications for Cancer Therapy

This review will focus on properties of cancer stem cells; will compare and contrast the cancer stem cell model with the clonal evolution model of tumorigenesis; will discuss the role of cancer stem cells in the development of resistance to chemotherapy; and will review the therapeutic implications and challenges of targeting cancer stem cells, with an assessment of the potential such an approach holds for improving outcomes for patients with cancer.


Laura Biganzoli, MD

Latest:

Further Thoughts on Adjuvant Treatment for Older Breast Cancer Patients

The adjuvant treatment of breast cancer is facing a challenging phase due to the increasing knowledge of breast cancer biology and consequent need to personalize treatments. Medical oncologists are asked to practice evidence-based medicine, but their approach is often based on results of trials conducted in extremely heterogeneous populations.


Laura Dominici, MD

Latest:

Lymph Node Staging in Localized Breast Cancer

In this interview we discuss the current guidelines for lymph node staging in breast cancer and dive into the debate surrounding sentinel node biopsies.


Laura Giffin Audell, MD

Latest:

Management of Pain in Special Populations of Cancer Patients

Children, the elderly, AIDS patients, and former narcotic drug abusers pose special problems in pain management that may lead to undermedication even more frequently than occurs in the general population of cancer patients with pain. A multidisciplinary panel of six pain experts with clinical experience in caring for these special groups met in Santa Fe, New Mexico, to discuss assessment methods and pharmacologic approaches to the treatment of pain in these patients. A summary of the roundtable discussion follows.


Laura Hardesty, MD

Latest:

Early-Stage BRCA2-Linked Breast Cancer Diagnosed in the First Trimester of Pregnancy Associated With a Hypercoagulable State

This feature examines the case of a patient with newly diagnosed breast cancer in the setting of a first-trimester pregnancy presenting to our multidisciplinary breast cancer clinic.


Laura Hohwü Thomsen, MD, PhD

Latest:

Ground-Glass Opacity Lung Nodules in the Era of Lung Cancer CT Screening: Radiology, Pathology, and Clinical Management

This review focuses on the radiologic and pathologic features of ground-glass opacity nodules, along with the clinical management of these lesions.


Laura Hoofring, RN, MS

Latest:

Management of Delirium

Ms. B is a 44-year-old married African-American female who was diagnosed with locally advanced right breast cancer in 2002. Immunohistochemistry in the original tumor was estrogen- and progesterone-receptor-negative, HER2-positive. Her past medical history is significant for hypertension and miscarriage in 1995.


Laura J. Esserman, MD, MBA

Latest:

Are We Overtreating DCIS?

With evidence from a number of studies, this presentation delves into the controversy surrounding the treatment, or overtreatment, of ductal carcinoma in situ (DCIS), and discusses whether or not these lesions should indeed be classified as breast cancer.


Laura J. Esserman, MD, MBA

Latest:

Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other’s Experiences

In this interview we review recent breast cancer screening guidelines from the ACS and USPSTF, and discuss the changing way that early-stage breast and prostate cancers are being treated.


Laura J. Rittmeyer, MS

Latest:

Mathematical Modeling for Breast Cancer Risk Assessment

Women at increased risk of breast cancer have important opportunities for early detection and prevention. There are, however, serious drawbacks to the available interventions. The magnitude of breast cancer risk is a crucial factor in the optimization of medical benefit when considering the efficacy of risk-reduction methods, the adverse effects of intervention, and economic and quality-of-life outcomes. Breast cancer risk assessment has become increasingly quantitative and is amenable to computerization. The assembly of risk factor information into practical, quantitative models for clinical and scientific use is relatively advanced for breast cancer, and represents a paradigm for broader risk management in medicine. Using a case-based approach, we will summarize the major breast cancer risk assessment models, compare and contrast their utility, and illustrate the role of genetic testing in risk management. Important considerations relevant to clinical oncology practice include the role of risk assessment in cancer prevention, the logistics of implementing risk assessment, the ramifications of conveying risk information with limited genetic counseling, and the mechanisms for genetics referral. Medical professionals can embrace new preventive medicine techniques more effectively by utilizing quantitative methods to assess their patients’ risks. [ONCOLOGY 16:1082-1099, 2002]


Laura J. Zitella, RN, MS, NP

Latest:

ONS: Infection Risk, Prevention, and Management

In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting-in both patients with solid tumors and those with hematologic malignancies.


Laura Jung, PharmD

Latest:

Discovery, Development, and Clinical Applications of Bortezomib

Proteasome inhibition is a novel, targeted approach in cancertherapy. Both natural and synthetic proteasome inhibitors selectivelypenetrate cancer cells, disrupting the orderly destruction of key regulatoryproteins involved in tumorigenesis and metastasis. Disrupting theorderly destruction of regulatory proteins causes an imbalance of theseproteins within the cell, which interferes with the systematic activationof signaling pathways required to maintain tumor cell growth and survival;therefore, cellular replication is inhibited and apoptosis ensues.


Laura L. Michaud, PharmD

Latest:

Anastrozole: A New Selective Nonsteroidal Aromatase Inhibitor

Endocrine therapy has long been a mainstay in the therapy of metastatic breast cancer and in the adjuvant setting. The introduction of anastrozole (Arimidex) to the market in 1996 has provided another option for such treatment. Drs. Goss and Tye provide a thorough review of anastrozole and outline its advantages over other aromatase inhibitors as adjuvant therapy for breast cancer and its potential use in the treatment of early breast cancer. The authors delineate many important issues regarding the use of anastrozole; an understanding of these issues is imperative for the optimal utilization of this therapy. The paper has two shortcomings: (1) It focuses almost solely on aromatase inhibitors, to the neglect of other endocrine therapies. (2) Many references are unconventional and represent data on file with various drug manufacturers, which are not easily accessible to readers.


Laura Liberman, MD

Latest:

Stereotactic Breast Biopsy: Indications and Results

This paper will address various issues relevant to core-needle biopsy of the breast under stereotactic imaging guidance. Patient and equipment selection, indications, contraindications, complications, limitations, and advantages will be discussed. The role of stereotactic core biopsy in patient management will also be addressed.


Laura Nadeau, MD

Latest:

How We Treat Tumor Lysis Syndrome

When tumor cells are rapidly broken down and their contents released into the extracellular space, the released ions and compounds can cause metabolic disturbances too great to be neutralized by the body's normal mechanisms.


Laura Phan, MPH

Latest:

HBV Vaccination Program Reduces Liver Cancer in Taiwan

Although liver cancer has a relatively low incidence in the United States, compared with other cancers, it is 10 times more common in many developing countries than in this country.[1] The incidence of liver cancer is highest in sub-Saharan Africa, China, southern Asia, and Japan.[2]


Laura Raftery, MD

Latest:

Cancer Management Chapter 12: Liver, gallbladder, and biliary tract cancers

Worldwide, hepatocellular carcinoma is the fifth most common malignancy and the third most common cause of cancer mortality. Most patients with hepatocellular carcinoma suffer from cirrhosis primarily caused by alcoholism or chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV); decades may pass between infection with viral hepatitis and development of this cancer. The approximately equal annual incidence and mortality of 1 million reported around the world stands as evidence of its lethality.


Laura S. Spruill, MD, PhD

Latest:

Improved Metastatic Uterine Papillary Serous Cancer Outcome With Treatment of Mast Cell Activation Syndrome

A 71-year-old woman not on hormone replacement therapy presented with uterine bleeding. Dilation and curettage revealed complex hyperplasia with atypia, focal clear-cell features, and endocervicitis. Endometrial intraepithelial carcinoma was suspected.


Laura Tenner, MD

Latest:

In Search of Value in Cancer Care: What Resources Are Available to Practicing Oncologists?

One of the more difficult topics to discuss concerning the ethics of healthcare is distributive justice-the fair distribution of benefits, risks, and costs.


Laurc A. Siminoff, PhD

Latest:

Commentary (Siminoff): Some Elements of Prognosis in Terminal Cancer

The ability to predict short- and long-term outcomes for cancer patients has become increasingly important. Changes in the way care is provided and paid for, along with a more consumerist attitude on the part of patients, have made this a more prominent issue.


Laurel J. Lyckholm, MD

Latest:

Giving Honest Information to Patients With Advanced Cancer Maintains Hope

Oncologists often do not give honest prognostic and treatment-effect information to patients with advanced disease, trying not to “take away hope.” The authors, however, find that hope is maintained when patients with advanced cancer are given truthful prognostic and treatment information, even when the news is bad.


Laurel Rice, MD

Latest:

Ovarian Cancer Surgical Practice Guidelines

The Society of Surgical Oncology surgical practice guidelines focus on the signs and symptoms of primary cancer, timely evaluation of the symptomatic patient, appropriate preoperative evaluation for extent of disease, and role of the surgeon in


Lauren A. Wiebe, MD

Latest:

Supportive Care of the Patient With Advanced Pancreatic Cancer

This review covers symptoms and complications in patients with late-stage pancreatic cancer, including venous thromboembolism, anorexia-cachexia, pain, and depression.